Co-existance of KRAS and LKB1 mutation as predictor of resistance to Erlotinib: Customized next-generation sequencing (NGS) of TAILOR trial.

Eliana Rulli,Mara Serena Serafini,Mirko Marabese,Elisa Caiola,Gabriella Sozzi,Massimo Moro,Emilio Bria,Michele Simbolo,Adele Busico,Elena Tamborini,Giulia Corrao,Gabriella Farina,Massimo Broggini,Monica Ganzinelli,Marina Chiara Garassino

Co-existance of KRAS and LKB1 mutation as predictor of resistance to Erlotinib: Customized next-generation sequencing (NGS) of TAILOR trial.

2017

Eliana Rulli
Mara Serena Serafini
Mirko Marabese
Elisa Caiola
Gabriella Sozzi
Massimo Moro
Emilio Bria
Michele Simbolo
Adele Busico
Elena Tamborini
Giulia Corrao
Gabriella Farina
Massimo Broggini
Monica Ganzinelli
Marina Chiara Garassino

e20631Background: The prognostic and predictive value of KRAS mutation in advanced NSCLC is still debatable. In TAILOR (NCT00637910) trial EGFR wild-type patients were randomized to receive 2nd lin...

Keywords:

Erlotinib
DNA sequencing
KRAS
Pathology
Cancer research
Mutation
Medicine
Oncology
predictive value
kras mutation
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations